Patent Application
20140309203
The invention relates to phytoecdysones, whether in pure form or contained in an extract, for their use in weight stabilization after a weight-loss diet.
More specifically, the invention makes it possible to avoid weight gain in obese mammals having previously undergone a weight-loss diet.
These days, overweight and obesity are physiopathological conditions that are steadily becoming more prevalent throughout the world. In Europe and the USA, an individual is considered overweight when his or her body mass index (BMI) is greater than 25. An individual is considered obese when his or her BMI is greater than 30.
This physiological disorder may be the source of many health complications. For example, metabolic syndrome is a physiological disturbance most often associated with being overweight. A person is recognized as having metabolic syndrome when he or she has at least three of the following five clinical signs associated with said condition:
visceral or abdominal obesity, hypertriglyceridemia, atherogenic dyslipidemia, hypertension, and hyperglycemia (Isomaa et al., 2001). Obesity itself also increases the risk of developing type 2 diabetes (or adult-onset diabetes) and cardiovascular diseases (Rexrode et al., 1998).
One method for an obese mammal to lose weight and body fat is to follow a hypocaloric diet, possibly in combination with drugs and/or dietary supplements, as well as regular physical activity. However, after an initial phase of weight loss, it is common to observe weight regain in individuals on a hypocaloric diet (Ulen et al., 2008). This phenomenon is known as the “rebound effect”.
Many dietary supplements and functional foods have been developed to promote weight loss in overweight mammals (Saper et al., 2004) and to prevent the development of diabetes (McWorther, 2001) and cardiovascular diseases. Most dietary products currently on the market are not effective enough on abdominal obesity, and in some cases, they were found to be toxic (Pittler et al., 2005). Furthermore, they lack the efficacy to prevent the rebound effect after a certain period of time on a hypocaloric diet.
It is therefore necessary to identify new natural molecules, already present in the diet of mammals, in order to develop ingredients and functional foods that are non-toxic and present long-term efficacy on body fat.
Phytoecdysones are plant-derived ecdysteroids. They are natural molecules that belong to the triterpene family and are relatively abundant in the plant kingdom, where they can be found in 5% of wild plants (Báthori and Pongracs, 2005).
As described in patent FR2924346 on behalf of the Applicant, phytoecdysones, and particularly 20-hydroxyecdysone, are known to reduce the increase of body fat in mammals on a fattening hypercaloric diet.
In addition, said molecules have antioxidant properties (Kuzmenko et al., 2001) and lack toxicity (Ogawa et al., 1974).
The inventors discovered that ingesting phytoecdysones, by obese mammals, can reduce weight regain following an initial phase of weight loss due to a hypocaloric diet.
More specifically, individuals being treated with phytoecdysones stabilize their weight, or even continue losing weight, over the course of a phase known as the stabilization phase, during which a control group regains weight.
Furthermore, during this stabilization phase, individuals being treated with phytoecdysones had a smaller adipocyte size than those in the control group. They also had lower blood insulin levels and greater insulin sensitivity than those in the control group.
The invention therefore proposes to implement phytoecdysones, specifically 20-hydroxyecdysone, to prevent weight regain in obese mammals on a hypocaloric weight-loss diet.
Preferably, phytoecdysones are also used to stabilize, or even continue to reduce, the diameter of adipocytes during the stabilization phase after a hypocaloric weight-loss diet.
Preferably, phytoecdysones are also used to stabilize insulin sensitivity that has improved due to a prior hypocaloric weight-loss diet. In addition to their effect in treating obesity, phytoecdysones are therefore promising in the treatment of diabetes, particularly type 2 diabetes.
The phytoecdysones that are used can be obtained by extraction from plants. Ecdysones prepared by hemisynthesis can also be used.
Phytoecdysones are preferably selected from 20-hydroxyecdysone, makisterone A, 24-epimakisterone A, 24(28)-dehydromakisterone A, 20,26-dihydroxyecdysone, and combinations of two or more of these components.
The phytoecdysones can be in pure form or contained in a more or less enriched plant extract. Advantageously, the phytoecdysones implemented according to the invention are in the form of a plant extract enriched with phytoecdysones, said extract containing at least 1% phytoecdysones by weight. Preferably, the extract contains between 1% and 7% phytoecdysones, more preferably between 1.5% and 3%, and even more preferably 2% phytoecdysones by weight.
Food plants from which the extracts according to the invention come are advantageously selected from chenopodiacae, particularly quinoa and spinach (Findeisen, 2004). Medicinal plants can also be used to develop extracts that are rich in phytoecdysones.
Preferably, a plant extract enriched with phytoecdysones according to the invention comes from quinoa. Quinoa is an edible pseudo-cereal that is rich in phytoecdysones (Zhu et al., 2001; Dini et al., 2005). It is thus possible to supplement food by ingesting extract of quinoa that has been enriched with phytoecdysones, by introducing said extract into a food, such as a milk product or a beverage, or by consuming it as a dietary supplement, such as in the form of a capsule.
Quinoa is currently known as the food plant that is the richest in phytoecdysones. Quinoa seeds contain a blend of phytoecdysones (Zhu et al., 2001). Said phytoecdysones are especially abundant in the shell of the quinoa seeds. For example, a 60-gram lot of quinoa seeds (dry weight) provides 15 to 25 milligrams of 20-hydroxyecdysone.
Phytoecdysones implemented according to the invention are advantageously in the form of a composition that can be orally administered.
Composition means, for example, a food product, such as a beverage, a milk product, or something else. Of course, the composition can be a medicinal composition, such as one used in the form of pills which thus contain an exact dose of phytoecdysones.
Advantageously, the phytoecdysones are orally administered at a rate of 0.3 to 2.0 mg per kg of body weight per day, preferably 0.5 mg per kg per day.
Another purpose of the invention is a method for preparing a quinoa extract enriched with one or more phytoecdysones, said method comprising the following steps:
The invention also relates to the quinoa extract resulting from the aforementioned method. Said extract can advantageously be used to avoid weight regain in obese mammals on a hypocaloric weight-loss diet, as described above.
In the invention, it is proposed to provide a dose of phytoecdysones in the form of purified molecules, or by means of a plant extract enriched with phytoecdysones, so as to prevent weight regain, known as the “rebound effect”, in obese mammals on a hypocaloric weight-loss diet.
According to the invention, it is possible to provide said dose of phytoecdysones in the form of a plant extract, such as quinoa, incorporated for example in food added to an individual's daily diet. One gram of quinoa that has been enriched with up to 2% phytoecdysones by weight contains 20 milligrams of phytoecdysones. To obtain the same quantity of phytoecdysones from quinoa seeds, it would be necessary to consume 50 grams of unprocessed quinoa seeds (Dini et al., 2005; Kumpun et al., 2011). The quinoa extract according to the invention may also contain up to 50 times more phytoecdysones than the quinoa seeds from which it is produced.
I—An example of a method for preparing the quinoa extract enriched with phytoecdysones (Extract A)
The quinoa seeds are first ground to separate the flour from the bran of the seed. An extraction is then carried out by adding 4,000 L to 400 kg of bran. The aqueous extract undergoes solid/liquid separation, followed by centrifugation. The resulting supernatant is subjected to 90° C. heat to precipitate the proteins. The aqueous extract is then purified by being passed through a column of food resin for the purpose of enriching it with phytoecdysones. The ethanol eluate is then dried by means of spray drying after adding a bit of maltodextrin, appropriated to adjust the 2±0.2% content in weight of 20-hydroyecdysone (20E).
Such a sequential extraction makes it possible to eliminate saponins from the extract, which are abundant in quinoa seeds (Muir et al., 2002) and which would create a bitter taste in said extract, and most sugars.
The obtained extract contains a blend of phytoecdysones, of which 85-90% is 20-hydroxyecdysone. The remainder is comprised of other very similar phytoecdysones, such as makisterone A, 24-epimakisterone A, 24(28)-dehydromakisterone A, 20,26-dicydroxyecdysone (Kumpun et al, 2011). The structures of these components are shown in
An extract similar to extract A, usable as part of the invention, is notably sold under the number Quinolia®.
II—A double-blind clinical trial on the effects of extract A on obese individuals on a hypocaloric diet for six weeks followed by a stabilization diet for six weeks
The effect of extract A was studied as part of a double-blind clinical trial on 60 overweight and obese volunteers, comprised of 18 men and 42 women with a BMI ranging from 27 to 38. The volunteers were given a hypocaloric diet of 1200 kcal for women and 1500 kcal for men for six weeks. The hypocaloric diet is followed by a six-week stabilization diet, with 20% more calories than the hypocaloric diet. Parameters such as insulin levels, weight change, adipocyte diameter, and muscle strength were measured during the visits at the start and end of the hypocaloric and stabilization phases.
Subjects were split into two groups. A first group (“extract A” group) received six capsules of extract A, containing a total of 40 mg of phytoecdysones, in three daily doses, throughout the duration of the test.
A second control group (“placebo” group) received six capsules of placebo in three daily doses, for the same duration.
Measurements were taken at the beginning of treatment (W0), at the end of the sixth week of the diet (W6), and at the end of the twelfth week of the diet (W12).
The effect of extract A during a hypocaloric diet was studied based on weight change (
The “placebo” and “extract A” groups showed respective weight losses of 4.05 kg and 3.86 kg during the first phase of the diet, called the weight-loss phase.
During the second phase of the diet, called the stabilization phase, the “extract A” group continued to lose weight (−0.483 kg), while the “placebo” group posted an average gain of +0.504 kg.
The study of relative weight change in the tested individuals shows that, in the “extract A” group, only 10% of individuals rebounded (a gain of 0.05 to 0.1 kg/day), compared to 28% of the “placebo” group.
The same “extract A” group had 20% of individuals who had lost 0.06 to 0.15 kg/day, while in the “placebo” group, only 10% of individuals fell into that category.
The effect of extract A during a hypocaloric diet was studied based on adipocyte diameter change (
During the weight-loss phase, the average adipocyte diameter was reduced both in the “extract A” group (−10.94 μm) and in the “placebo” group (−8.80 μm).
During the stabilization phase, the average diameter continued to decline, with a significant difference between the “extract A” group (−9.25 μm) and the “placebo” group (−5.99 μm) group.
This result is combined with a greater loss in body fat during the stabilization phase in the “extract A” group. In fact, the loss of body fat during the stabilization phase was −0.74 kg for the “extract A” group, but only −0.33 kg for the “placebo” group.
The effect of extract A during a hypocaloric diet was studied based on the change in insulin levels (
Blood insulin levels declined during the weight-loss phase in the “extract A” group (−18.90 pmol/L) and the “placebo” group (−12.60 pmol/L). They climbed back up during the stabilization phase in the “placebo” group (7.69 pmol/L), but they stabilized in the “extract A” group. The treatment with extract A makes it possible to stability blood insulin levels in the stabilization phase and to decrease them significantly more than placebo throughout treatment.
Insulin resistance, measured with the HOMA-IR index, declined in both groups during the weight-loss phase. It remained constant in the “extract A” group during the stabilization phase, but it went back up significantly in the “placebo” group.
The administration of extract A makes it possible for object subjects to avoid weight regain during the second phase, called the stabilization phase, of the hypocaloric weight-loss diet.
Furthermore, the administration of extract A allows for a more significant decline in body fat and average adipocyte diameter during the stabilization phase.
The administration of extract A finally makes it possible to lower insulin levels and maintain the improved insulin sensitivity brought about by the hypocaloric diet during this same phase.
In: Invertebrate Endocrinology and Hormonal Heterophylly (Burdette, W. J. ed.) Springer, New York.341-344.
| Number | Date | Country | Kind |
|---|---|---|---|
| 1160280 | Nov 2011 | FR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/FR2012/052600 | 11/12/2012 | WO | 00 | 5/7/2014 |
